XAIR
Beyond Air, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$2.14
−1.16%Oct 8, 2026, 12:00 UTC
Beyond Air announced preliminary, unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026, its highest quarterly revenue, up approximately 30% sequentially and 27% year over year.
Source:Sep 24, 2026, 20:37 UTC
Beyond Air, Inc. amended the employment agreement of Chief Financial Officer Daniel Moorhead, raising his annual base salary from $325,000 to $463,000 effective September 23, 2026.
Sep 24, 2026, 20:37 UTC
Beyond Air, Inc. entered into an employment agreement with Robert Goodman as Chief Executive Officer, effective September 23, 2026, providing an annual base salary of at least $650,000 and a target bonus of 60% of base salary.
Aug 31, 2026, 12:00 UTC
The U.S. Food and Drug Administration granted Breakthrough Device Designation to Beyond Air's LungFit GO for the treatment of nontuberculous mycobacterial pulmonary disease.
Source:Aug 25, 2026, 11:00 UTC
Beyond Air entered a definitive agreement to sell its NeuroNOS stake to UNIVO Pharmaceutical Industries in exchange for equity and milestone payments.
Source:Aug 13, 2026, 11:00 UTC
Beyond Air reported financial results for the quarter ended June 30, 2026, with revenue of $1.8 million, and reaffirmed revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027.
Jul 31, 2026, 00:00 UTC
Beyond Air, Inc. entered into a private placement offering of common stock, pre-funded warrants, and Series A and Series B warrants, raising approximately $10.2 million upfront and up to $30.1 million if all warrants are exercised.